drugset / Trial / NCT03000179
Safety and Efficacy of Avelumab in Small Intestinal Adenocarcinoma
Phase 2
Terminated
8 enrolled
Vanderbilt-Ingram Cancer Center
EMD Serono · collabNational Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single-agent, open label, one-arm phase 2 pilot study of avelumab in patients with advanced or metastatic adenocarcinoma of the small intestine.
Timeline
- Start
- 2017-03-03
- Primary completion
- 2021-08-03
- Completion
- 2021-08-03
Outcome
Outcome not reported
Stopped (Enrollment): “Low accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Avelumab | Monoclonal antibody | — | Intravenous |